Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)

Objective:The ACTION (Assessment of Cost and ouTcomes of chemotherapy In an Observational setting) study investigated associations between chemotherapy, patient/disease characteristics and outcomes in advanced non-small cell lung cancer (NSCLC) patients in clinical practice.Research design and metho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bischoff, Helge (VerfasserIn) , van den Borne, Ben (VerfasserIn) , Pimentel, Francisco L. (VerfasserIn) , Arellano, Jorge (VerfasserIn) , Langer, Frank (VerfasserIn) , Leschinger, Monika I. (VerfasserIn) , Thatcher, Nicholas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 15 Apr 2010
In: Current medical research and opinion
Year: 2010, Jahrgang: 26, Heft: 6, Pages: 1461-1470
ISSN:1473-4877
DOI:10.1185/03007991003799180
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1185/03007991003799180
Volltext
Verfasserangaben:Helge G. Bischoff, Ben van den Borne, Francisco L. Pimentel, Jorge Arellano, Frank Langer, Monika I. Leschinger, Nicholas Thatcher

MARC

LEADER 00000caa a2200000 c 4500
001 183342610X
003 DE-627
005 20230710160645.0
007 cr uuu---uuuuu
008 230207s2010 xx |||||o 00| ||eng c
024 7 |a 10.1185/03007991003799180  |2 doi 
035 |a (DE-627)183342610X 
035 |a (DE-599)KXP183342610X 
035 |a (OCoLC)1389821953 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bischoff, Helge  |d 1958-  |e VerfasserIn  |0 (DE-588)111184576  |0 (DE-627)389658286  |0 (DE-576)167287249  |4 aut 
245 1 0 |a Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)  |c Helge G. Bischoff, Ben van den Borne, Francisco L. Pimentel, Jorge Arellano, Frank Langer, Monika I. Leschinger, Nicholas Thatcher 
264 1 |c 15 Apr 2010 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 07.02.2023 
520 |a Objective:The ACTION (Assessment of Cost and ouTcomes of chemotherapy In an Observational setting) study investigated associations between chemotherapy, patient/disease characteristics and outcomes in advanced non-small cell lung cancer (NSCLC) patients in clinical practice.Research design and methods:Chemonaïve NSCLC patients from five European countries were observed for 18 months from initiation of first-line chemotherapy; care was at the physician’s discretion.Main outcome measures:Survival and associated prognostic factors were estimated using Kaplan-Meier methods and a Cox proportional hazards model, respectively. Cluster analyses of baseline patient characteristics were also performed. Toxicity data were not considered in these analyses.Results:A total of 975 eligible patients with NSCLC (Stage IIIb/IV) were enrolled and provided baseline and response data; cluster analysis was performed on 829 patients and survival data were available from 906 patients. In first-line treatment, a 39.8% response rate, a 39.5% 1-year survival rate and unadjusted median survival of 9.3 months were observed. Prognostic factors for survival included performance status (PS), number of metastatic organs, gender and age. Five patient clusters were identified, highlighting patient heterogeneity in terms of baseline condition and age. PS was maintained or improved throughout first-line and second-line chemotherapy in half the patients receiving these treatments.Conclusions:ACTION provides valuable information about patient population, disease characteristics, treatment choices, prescribing patterns and outcomes in routine clinical practice in advanced NSCLC in Europe. Our findings suggest that maintenance of PS after first and subsequent lines of chemotherapy, and survival rates may both be higher than previously anticipated. Our results also showed an association between age and survival, which suggests that age should not exclude patients from receiving chemotherapy if they meet all other eligibility criteria. 
650 4 |a Chemotherapy 
650 4 |a Cluster analysis 
650 4 |a NSCLC 
650 4 |a Observational studies 
650 4 |a Prognostic factors 
650 4 |a Survival 
700 1 |a van den Borne, Ben  |e VerfasserIn  |4 aut 
700 1 |a Pimentel, Francisco L.  |e VerfasserIn  |4 aut 
700 1 |a Arellano, Jorge  |e VerfasserIn  |4 aut 
700 1 |a Langer, Frank  |e VerfasserIn  |4 aut 
700 1 |a Leschinger, Monika I.  |e VerfasserIn  |4 aut 
700 1 |a Thatcher, Nicholas  |e VerfasserIn  |0 (DE-588)1144315514  |0 (DE-627)1004522843  |0 (DE-576)495342858  |4 aut 
773 0 8 |i Enthalten in  |t Current medical research and opinion  |d Abingdon : Taylor & Francis Group, 1972  |g 26(2010), 6, Seite 1461-1470  |h Online-Ressource  |w (DE-627)325162158  |w (DE-600)2034331-0  |w (DE-576)325002673  |x 1473-4877  |7 nnas  |a Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study) 
773 1 8 |g volume:26  |g year:2010  |g number:6  |g pages:1461-1470  |g extent:10  |a Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study) 
856 4 0 |u https://doi.org/10.1185/03007991003799180  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20230207 
993 |a Article 
994 |a 2010 
998 |g 111184576  |a Bischoff, Helge  |m 111184576:Bischoff, Helge  |d 910000  |d 950000  |d 950900  |e 910000PB111184576  |e 950000PB111184576  |e 950900PB111184576  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/ 
999 |a KXP-PPN183342610X  |e 4268343881 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"role":"aut","given":"Helge","family":"Bischoff","display":"Bischoff, Helge"},{"display":"van den Borne, Ben","family":"van den Borne","role":"aut","given":"Ben"},{"family":"Pimentel","display":"Pimentel, Francisco L.","role":"aut","given":"Francisco L."},{"given":"Jorge","role":"aut","display":"Arellano, Jorge","family":"Arellano"},{"role":"aut","given":"Frank","display":"Langer, Frank","family":"Langer"},{"role":"aut","given":"Monika I.","display":"Leschinger, Monika I.","family":"Leschinger"},{"display":"Thatcher, Nicholas","family":"Thatcher","role":"aut","given":"Nicholas"}],"relHost":[{"language":["eng"],"part":{"issue":"6","text":"26(2010), 6, Seite 1461-1470","year":"2010","pages":"1461-1470","volume":"26","extent":"10"},"recId":"325162158","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2034331-0"],"issn":["1473-4877"],"eki":["325162158"]},"note":["Gesehen am 03.02.23"],"pubHistory":["1.1972/73 -"],"origin":[{"publisherPlace":"Abingdon ; Reading ; London","publisher":"Taylor & Francis Group ; Librapharm ; Informa Healthcare","dateIssuedKey":"1972","dateIssuedDisp":"1972-"}],"title":[{"title":"Current medical research and opinion","title_sort":"Current medical research and opinion"}],"disp":"Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)Current medical research and opinion","type":{"media":"Online-Ressource","bibl":"periodical"}}],"recId":"183342610X","name":{"displayForm":["Helge G. Bischoff, Ben van den Borne, Francisco L. Pimentel, Jorge Arellano, Frank Langer, Monika I. Leschinger, Nicholas Thatcher"]},"physDesc":[{"extent":"10 S."}],"id":{"eki":["183342610X"],"doi":["10.1185/03007991003799180"]},"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"15 Apr 2010"}],"note":["Gesehen am 07.02.2023"],"title":[{"title_sort":"Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)","title":"Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} 
SRT |a BISCHOFFHEOBSERVATIO1520